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Context: Cholesteryl ester transfer protein (CETP) regulates high density lipoproteins (HDL)-63 
cholesterol levels and interaction between glucose and HDL metabolism is central in the development 64 
of diabetes. 65 
Objective: We hypothesized that CETP levels would be regulated in diabetic pregnancies. We tested 66 
the hypothesis by evaluating CETP activity measured multiple times during pregnancy and at 5 years 67 
follow-up in a prospective cohort (STORK) and investigated its association with gestational diabetes 68 
mellitus (GDM) during pregnancy or development of prediabetes 5 years after pregnancy. We also 69 
evaluated the strongest correlated of CETP activity among measures of adipocity and glucose 70 
metabolism, lipoproteins, adipokines and monocyte/macrophage activation markers. 71 
Design: Population-based longitudinal cohort study from 2001 to 2013. 72 
Setting: Oslo University Hospital. 73 
Patients or other Participants: 300 women during pregnancy and at 5 years postpartum. 74 
Main Outcome Measures:  CETP activity measured at 14-16, 22-24, 30-32, 36-38 weeks gestation, 75 
and at 5 years follow-up. 76 
Results: We found higher CETP activity in pregnancy in women developing prediabetes but no 77 
association with GDM. CETP activity decreased throughout pregnancy and remained low at follow-78 
up. High CETP activity was associated with sCD14 levels, in particular in women who developed 79 
prediabetes. These data show that enhanced CETP activity during pregnancy is associated with 80 
systemic indices of monocyte/macrophage activation, in particular in women who develop prediabetes 81 
later in life. 82 





Precis: Our study shows that CETP activity during pregnancy identified women at risk for later 86 




CETP  Cholesteryl ester transfer protein 91 
GDM  Gestational diabetes mellitus 92 
HDL  High density lipoproteins 93 
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OGTT  Oral glucose tolerance test 95 
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Both the number and composition of lipoprotein particles change during pregnancy. Early pregnancy 118 
is characterized by increased hepatic production and systemic removal of triglycerides (TG), with 119 
deposition of fat in maternal adipose tissue. Later, TG levels rise markedly, and high levels of TG-120 
enriched lipoproteins are observed mainly due to estrogen-driven hepatic synthesis of very low density 121 
lipoprotein (VLDL) and attenuated removal of TG. The abundance of VLDL TG accelerates transfer 122 
of TG to lipoproteins of higher density by cholesteryl ester transfer protein (CETP). Thus, through 123 
enhanced CETP activity high density lipoprotein (HDL) becomes progressively poorer in cholesterol 124 
ester and richer in TG (1).  125 
Circulating CETP is mainly bound to HDL and mediates the transfer of cholesterol ester to 126 
pro-atherogenic non-HDL fractions (ApoB, LDL, VLDL and IDL) in exchange for TG (2, 3). 127 
Increased CETP activity may increase TG in the HDL core, resulting on lower plasma HDL 128 
cholesterol (HDL-C) with potentially pro-atherogenic net effects. Elevated CETP activity has been 129 
observed in insulin resistance conditions, like obesity and type 2 diabetes (4). Inhibition of CETP 130 
substantially increases HDL-C and reduces non-HDL-C levels (2). A recent meta-analysis indicated 131 
that CETP inhibitor therapy significantly (12 %) reduced the incidence of diabetes (5). Large clinical 132 
studies using CETP inhibition therapy investigating cardiovascular outcome showed only modest 133 
improvements in prognosis, although a significant reduction in cardiovascular events was observed in 134 
the REVEAL study in combination with statins, and the beneficial effect also improved glycaemic 135 
control (6).  136 
Low HDL-C is associated with insulin resistance and development of diabetes (7). It is not 137 
known whether a low HDL level is causal, but there is evidence that HDLs enhances insulin synthesis, 138 
secretion and has anti-apoptotic effect on pancreatic beta-cells (8, 9). Further, HDLs have anti-diabetic 139 
effects in adipose tissue and enhance glucose uptake by skeletal muscle (3). Low HDL-C is observed 140 
in gestational diabetes mellitus (GDM) (10) and during long-term follow-up after a GDM diagnosis 141 
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(11). Prediabetes is shown to have an increased risk, in addition to type 2 diabetes, of cardiovascular 142 
disease and all-cause mortality (12) giving this group a high priority in optimizing glycemic control. 143 
Based on the role of CETP in regulating HDL-C levels and interaction between glucose and 144 
HDL metabolism in the development of diabetes, we hypothesized that CETP levels would be 145 
regulated in diabetic pregnancies. We therefore evaluated CETP activity measured multiple times 146 
during pregnancy and at 5 years follow-up in a prospective cohort (STORK) of 300 women and 147 
investigated its association with i) GDM during pregnancy and the development of prediabetes 5 years 148 
after pregnancy, and ii) measures of adipocity and glucose metabolism, lipoproteins, adipokines and 149 
monocyte/macrophage activation markers. 150 
Material and Methods 151 
The STORK study, a prospective longitudinal cohort study in which 1031 low-risk women of 152 
Scandinavian heritage were followed throughout their pregnancy and gave birth at Oslo University 153 
Hospital, Rikshospitalet between 2002 and 2008 (13). The exclusion criteria were multiple 154 
pregnancies, known pre-gestational diabetes and any severe chronic diseases (lung, cardiac, 155 
gastrointestinal or renal). Each pregnant woman had four study-related antenatal visits at weeks 14-16, 156 
22-24, 30-32, and 36-38. A 75g OGTT was performed in all women at 14-16 and again at 30-32 157 
weeks of gestation. All women were invited to participate in a 5-year postpartum follow-up study of 158 
whom 300 from the original study agreed (14). We included only the women who had participated 159 
both during pregnancy and follow-up in this particular study. Women with preeclampsia were 160 
excluded, and this study ended up with 290 participants. Subcutaneous fat at the triceps, subscapular, 161 
and iliac sites were estimated during pregnancy using a Holtain caliper (Holtain, Crymych, UK). 162 
Written informed consent was obtained from all study participants. All clinical investigations were 163 
conducted in accordance with the principles enshrined in the Declaration of Helsinki. The study was 164 
approved by the Regional Committee for Medical Research Ethics of Southern Norway in Oslo, 165 
Norway. 166 
Measurements of glucose and insulin from OGTT 167 
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All 75g OGTTs were performed in the morning after an overnight fast and glucose levels measured as 168 
previously reported (14). Briefly, venous blood was drawn in gel tubes, allowed to clot for 30 min, 169 
thereafter centrifuged for 10 min 3000 g, serum separated and stored at −80 °C. Glucose was measured 170 
in serum samples collected at antenatal visits at 14 -16 and 30–32 weeks and frozen until analysis, 171 
using the hexokinase method at an accredited clinical chemistry laboratory at Oslo University Hospital 172 
(Cobas 6000 from Roche). For the 5-year follow-up visit, fasting glucose measurements were 173 
collected using an Accu-check Sensor glucometer (Roche Diagnostics), using venous EDTA blood 174 
analyzed on site, as previously reported (14). Insulin levels were assayed in duplicate (RIA, DPC, Los 175 
Angeles, CA, USA) as previously reported (14, 15). 176 
Diagnosis of GDM and pre-diabetes 177 
GDM was diagnosed using the WHO2013 criteria (fasting plasma glucose (FPG) 5.1–6.9  mmol/L, 1h 178 
plasma glucose ≥10.0 mmol/L or 2h plasma glucose 8.5–11.0 mmol/L), at any time in pregnancy 179 
following a 75 g oral glucose load. Pre-diabetes was diagnosed at the 5-year follow-up visit using the 180 
following criteria: FPG 5.6–6.9 mmol/L or 2h plasma glucose 7.8–11.0  mmol/L after 75 g OGTT (16).  181 
Insulin sensitivity was measured with the Matsuda index 10 000/√ of (fasting glucose 182 
(mmol/L)×fasting insulin (mU/L)×(mean glucose (mmol/L)×mean insulin (mU/L)) during 75g OGTT. 183 
This index is a measure of whole body insulin sensitivity that has been validated against the 184 
euglycemic-hyperinsulinemic clamp (17). β-cell function was assessed with the insulin secretion-185 
sensitivity index (ISSI-2) (area under the curve insulin(mU/L)0−120 /glucose(mmol/L)0−120 ×Matsuda), 186 
validated against the disposition index from the intravenous glucose tolerance test (18). HOMA-IR 187 
was calculated as fasting insulin (mU/L)×fasting glucose (mmol/L)/22.5, as described by Matthews et 188 
al. (19).  189 
Lipoproteins and lipids 190 
Lipoproteins and lipids were measured at an accredited laboratory at Oslo University Hospital, 191 
Rikshospitalet. Total cholesterol, HDL-C and triglycerides were measured at weeks 14-16 and 36-38 192 
during pregnancy, as previously reported (Roland et al, under review). LDL-C was determined by 193 
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Friedewald's formula (20). Levels of HDL-C, LDL-C (directly measurements), and triglycerides (TG) 194 
were measured at follow-up as previously reported (11). 195 
 196 
Measurement of adipokines, monocyte/macrophage and inflammatory markers 197 
Peripheral venous blood was drawn into pyrogen-free tubes with EDTA as anticoagulant. The tubes 198 
were immediately immersed in melting ice and centrifuged within 30 minutes at 2,000g for 20 minutes 199 
to obtain platelet-poor plasma. All samples were stored at -80°C and thawed <3 times. Adipokines 200 
(adiponectin (DY1065), chemerin (DY2324), leptin (DY398), resistin (DY1359)), 201 
monocyte/macrophage markers (sCD163 (DY1607), sCD14 (DY383)) and the inflammatory marker 202 
CRP (DY1707) were measured in duplicate using commercially available antibodies (R&D Systems, 203 
Minneapolis, MN, USA) as previously reported (21-23) using a 384 format using the combination of a 204 
SELMA (Jena, Germany) pipetting robot and a BioTek (Winooski, VT, USA) dispenser/washer 205 
(EL406). Absorption was read at 450 nm with wavelength correction set to 540 nm using an ELISA 206 
plate reader (Synergy H1 Hybrid, Biotek, Vinooski, VT, USA). Intra- and inter-assay coefficients of 207 
variation were <10% for all assays. 208 
Measurement of CETP activity 209 
Plasma CETP activity was measured in duplicate using commercially available kit (MAK106) from 210 
Sigma-Aldrich (St. Louis, MO). The reaction mixture contained a donor molecule that was a 211 
fluorescent self-quenching neutral lipid as well as an acceptor molecule. Five µL of diluted plasma 212 
sample was added to the reaction mixture and incubated for 3 hours at 37°C in a black 384 well plate. 213 
CETP-mediated transfer from donor to acceptor resulted in an increase in fluorescence intensity with 214 
an excitation wavelength of 465 nm and emission of 535 nm as read by the fluorescent plate reader. 215 
The CV for the analysis was <13 %. All 5 samples from one person were analyzed on the same plate. 216 
Statistical analysis 217 
Statistical analyses were conducted using SPSS for Windows, version 21.0. Data are 218 
expressed as mean (SD) when normally distributed and median (25th, 75th percentile) when skewed. 219 
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For comparison of demographic and baseline data between prediabetes women vs. non-diabetes 220 
women, or GDM vs. non-GDM, students t-test or Mann–Whitney's U test were used depending on 221 
distribution, and χ2 test for categorical variables (Table 1 and 2). Temporal changes in CETP activity, 222 
lipoproteins, and inflammatory markers were assessed with repeated measures ANOVA, and if  the 223 
group effect was significant, multivariate linear regression analyses were carried out on log 224 
transformed variables (if skewed) at each visit, adjusting for age and BMI. These data are reported as 225 
back-transformed estimated marginal means with 95% confidence intervals (Figure 1, Figure 2 and 226 
Table 3). For evaluating predictors of CETP values at each individual time-point, we used stepwise 227 
linear regression (Table 4). To identify the strongest predictors of prediabetes and 2h glucose during 228 
OGTT using logistic and linear regression, respectively, we first performed univariate analysis and 229 
included all variables with p<0.2 in the adjusted multivariable analysis (Table 5). In addition, the 230 
modifying effect of each confounding variable in Table 5 on the association between CETP and 231 
prediabetes and 2-h glucose at 5 years follow-up was assessed using linear and logistic regression 232 
(Table 6). Spearman correlation was used when analyzing correlation between CETP activity and 233 
sCD14 at different time-points (Figure 3). Interaction analysis on 2-hour glucose levels as dependent 234 
and CETP and sCD14 at 14-16 weeks as independent was performed with both proteins and their 235 
product (Figure 3E). To visualize this we divided CETP and sCD14 in tertiles and graphed their 236 
product in relation to 2-hour glucose levels. This gave 6 groups (Figure 3F): group 1: Tertile 1 (T1) of 237 
both CETP and sCD14; group 2: combinations of T1 and T2 of CETP and sCD14; group 3: 238 
combinations of T1 and T3 of CETP and sCD14; group 4: T2 of both; group 5: combinations of T2 239 
and T3 of CETP and sCD14; group 6: T3 of both. P-values are two-sided and p<0.05 was considered 240 




Table 1 shows the characteristics of the prediabetes population (i.e. FPG 5.6–6.9 mmol/L or 2h plasma 245 
glucose 7.8–11.0 mmol/L after 75 g OGTT) vs. the non-diabetes population at 5 years follow-up and 246 
retrospective during pregnancy. Table 2 shows the characteristics of the GDM diagnosed with the 247 
10 
 
WHO 2013 diagnostic criteria vs. non-GDM women at the same timepoints. Briefly, GDM women 248 
were older and had a higher BMI and weight than controls while the prediabetes women only had 249 
higher weight during pregnancy and elevated BMI at 5 years follow-up. Systolic blood pressure was 250 
higher in GDM while diastolic blood pressure was higher in prediabetes. Indices of glucose 251 
metabolism were dysregulated in both the GDM and prediabetes group. 252 
Lipoproteins and lipids in GDM and prediabetes 253 
We have previously presented lipoprotein levels (Roland et al, submitted) and cardio-metabolic lipid 254 
ratios during pregnancy and at 5 years follow-up (11). In the present study we found a similar 255 
lipoprotein dysregulation in prediabetes as in GDM characterized by low HDL-C at week 14-16, and 256 
low HDL-C, high TG and TG/HDL ratio at 5 years follow-up (Figure 1).  257 
CETP activity in GDM and women who develop prediabetes 258 
Evaluating women identified with prediabetes at 5 years follow-up (n=20) during pregnancy revealed 259 
elevated levels of CETP activity at 14-16 weeks, 22-24 weeks, 30-32 weeks and 36-38 weeks. Of 260 
these prediabetes women at 5 years follow-up, 14 were diagnosed with GDM and 6 were not 261 
diagnosed with GDM during pregnancy (Figure 2). We found no difference in CETP activity between 262 
GDM (n=70) and non-GDM (n=215) at any time point during pregnancy or at follow-up. 263 
Preeclampsia patients were excluded from the analysis.  264 
CETP activity associations with clinical markers, glucose tolerance, lipoproteins, inflammatory 265 
markers, monocyte/macrophage markers and adipokines 266 
We next evaluated predictors of CETP levels at 14-16 weeks, 30-32 weeks and at 5 years follow-up 267 
using variables obtained at the same time-point. As seen in Table 4, CETP activity correlated with 268 
subcutaneous fat in the iliaca region, but not triceps or BMI. Further, CETP was modestly associated 269 
with indices of glucose metabolism. For lipoproteins, a positive association with LDL-C at 14-16 270 
weeks, at term and follow-up was observed while a negative correlation with HDL-C was seen at 14-271 
16 weeks, and a negative association with TG at term.  272 
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We have previously measured adipokines, monocyte/macrophage and inflammatory markers 273 
in this cohort (22). As seen in Table 4, leptin, resistin, chemerin, sCD163, sCD14, CRP were 274 
positively correlated with CETP activity during pregnancy. Soluble CD163 and sCD14 were also 275 
associated with CETP activity at 5 years follow-up. Multivariable linear regression, revealed sCD14 as 276 
the strongest determinant of CETP activity during and after pregnancy. Levels of these markers in 277 
women who developed prediabetes and non-diabetes are shown in Table 3. 278 
Association between CETP activity and sCD14 during pregnancy 279 
As described above, sCD14 was consistently one of the strongest predictors of CETP activity. 280 
Figure 3A shows CETP activity and sCD14 levels at 14-16 weeks as well as the AUC for these 281 
markers during pregnancy. A similar pattern of CETP activity and sCD14 was observed across the 282 
different groups of normal pregnancy, GDM and prediabetes. Figure 3C shows the correlation 283 
between AUCs for sCD14 and CETP activity indicating a stronger correlation in women who became 284 
prediabetic at follow-up. This correlations was evident at all time-points during pregnancy (Figure 3D) 285 
but lacking in GDM women. Finally, regression analysis of sCD14 and CETP at 14-16 weeks as 286 
predictors of 2-hour glucose at follow-up reveled an interaction (Figure 3E). To visualize this we 287 
graphed the product of tertiles of both proteins giving six groups (See statistical methods and Figure 288 
3F). As shown in Figure 3F, the 3 first groups had similar 2-hour glucose levels, including group 3 289 
which consisted of combinations of tertile 1 and 3 of CETP or sCD14, indicating that having high 290 
levels of CETP alone is not associated with future prediabetes. However combinations of tertile 2 and 291 
3 of CETP and sCD14 had higher levels of 2-hour glucose than the other groups indicating that high 292 
levels of both are more strongly associated with prediabetes. 293 
 294 
Elevated CETP activity early in pregnancy predicts prediabetes 5 years after pregnancy 295 
Logistic regression investigating the strongest early predictors of prediabetes (i.e. at week 14-16) 296 
found CETP (OR [CI]: 2.13 [1.18-3.81], p=0.012) and β-cell function (0.35 [0.19-0.66] p=0.001) as 297 
predictors of prediabetes at 5 years follow-up. Using linear regression and evaluating glucose 298 
tolerance as a continuous measure identified β-cell function (Slope -0.22 95% CI (-0.34 – -0.10), 299 
12 
 
p<0.001) and CETP (Slope 0.15 (0.03 – 0.27), p=0.012) at week 14-16 as the strongest predictors of 2 300 
hours glucose during OGTT at 5 years follow-up (Table 5). 301 
Discussion 302 
Our prospective cohort study evaluating CETP activity during pregnancy in normal and GDM women 303 
and in prediabetes 5 years follow-up revealed i) higher CETP activity in pregnancy in women 304 
developing prediabetes but no association with GDM ii) CETP activity decreased throughout 305 
pregnancy and remained low at follow-up iii) high CETP activity was associated with sCD14 levels, in 306 
particular in women who developed prediabetes and iv) CETP measurements during pregnancy was an 307 
independent and strong predictor of developing prediabetes 5 years after delivery. These data show 308 
that enhanced CETP activity during pregnancy is associated with development of prediabetes after 309 
pregnancy, but not with GDM, potentially involving interaction with monocyte/macrophage 310 
activation. 311 
The protective role of HDL has been ascribed to its capacity to promote reverse cholesterol 312 
transport from peripheral cells and deliver it to the liver for excretion. CETP is an important factor in 313 
HDL metabolism and reciprocal changes in CETP activity and HDL plasma levels are well 314 
documented (1). Elevated CETP activity during second trimester has been reported in normolipidemic 315 
healthy women, coinciding with the greatest increase in LDL- and HDL TG content, with similar 316 
changes during pregnancy and postpartum as shown in the present study (1, 24). While CETP was 317 
negatively associated with HDL activity early in pregnancy and positively with LDL during pregnancy 318 
and at follow-up, these correlations were modest in the present study. Instead, the 319 
monocyte/macrophage markers sCD163 and in particular sCD14, were positively associated with 320 
CETP activity both during pregnancy and at follow-up, supporting a link between 321 
monocyte/macrophage activation and CETP activity. Plasma CETP levels have previously been shown 322 
to correlate with liver macrophage content and it has been suggested that hepatic macrophages are the 323 
main producer of plasma CETP (25). Moreover, large increase in macrophage content in skeletal 324 
muscle and increase in CETP plasma levels after high fat diet has been documented (26). Obesity is 325 
associated with a lower HDL-mediated cholesterol efflux from macrophages and higher CETP activity 326 
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(27). It is therefore possible that CETP could be an important mediator linking HDL-C and 327 
inflammation with macrophages as a crucial cell. Based on our data, these mechanisms could 328 
potentially also contribute to the development of prediabetes following pregnancy. 329 
The main finding of our study was that CETP activity during pregnancy identified women at 330 
risk for later diabetes development, regardless of GDM status, which to our knowledge has not 331 
previously been reported. Furthermore, the association between sCD14 and CETP activity was much 332 
stronger in women who developed prediabetes compared to both women with uncomplicated 333 
pregnancy and GDM. Although sCD14 levels were not significantly different between women with 334 
normal pregnancy and those who developed prediabetes, there was a uniform trend of higher sCD14 335 
levels in prediabetic women and stronger correlation between sCD14 and CETP activity at all-time-336 
points during pregnancy. Furthermore, of all variables including measures of adipocity, lipoproteins, 337 
indices of glucose metabolism and inflammatory markers, sCD14 was consistently identified as a 338 
strong predictor of CETP both during pregnancy and at 5-year follow-up. Furthermore, the statistical 339 
interaction between CETP and sCD14 at 14-16 weeks in predicting 2-hour glucose further supports a 340 
link between CETP activity, monocyte/macrophage activation and diabetes. Although sCD163 also is 341 
a monocyte/macrophage activation marker, the lack of regulation in women who develop prediabetes 342 
could suggest that sCD14 is reflecting M1 activation since sCD163 is considered a M2 marker (28). 343 
Indeed, enhanced activation of CD14+ monocytes with increased ability for endothelial cell 344 
attachment has been described in diabetes (29) and polarization towards a pro-inflammatory M1 345 
phenotype has been demonstrated in prediabetes (30). Monocyte/macrophage activation occurs during 346 
normal pregnancy and although the precise mechanisms are unknown, exposure of maternal blood to 347 
placental cells or inflammatory products from these may activate them towards a pro-inflammatory 348 
phenotype (31). During LPS/TLR4 interaction sCD14 is released from monocytes/macrophages and 349 
notably, LPS from gut microbiota could interact with monocytes/macrophages outside the intestine 350 
through gut leakage mechanisms into the systemic circulation, which could be particular relevant 351 
during pregnancy (32). We recently demonstrated enhanced sCD163 in early GDM pregnancies with 352 
an inverse association with β-cell function, particularly in women with high BMI (22).  353 
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In the present study, β-cell function and CETP activity at 14-16 weeks gestation were the 354 
strongest predictors of prediabetes and the 2h OGTT glucose at 5 years follow-up. Thus, based on the 355 
strong correlation between sCD14 and CETP in women who developed prediabetes, our study may 356 
reflect the importance of monocyte/macrophage activation in the initiation of diabetic complications, 357 
possibly involving CETP related mechanisms. However, within the prediabetes group, the correlation 358 
between CETP activity and sCD14 was not present post-partum indicating that interactions between 359 
monocyte/macrophage activation and CETP may be more dominant during metabolic stress as in 360 
pregnancy.  361 
An interaction between monocyte/macrophage activation and CETP activity may also be 362 
relevant for adipose tissue as cross-talk between these cells may influence obesity associated insulin 363 
resistance as well as progression of atherosclerosis (33). Increased CD14 content in epicardial adipose 364 
tissue has been demonstrated in type 2 diabetes (34). In addition to reflecting monocyte/macrophage 365 
activation, CD14 may also directly modulate adipose tissue inflammatory activity and insulin 366 
resistance (35). CETP is also expressed in human adipose tissue (36). Plasma CETP is positively 367 
correlated with its mRNA expression in pericardial fat (37), and overexpression of CETP in mouse 368 
adipose tissue elevates plasma CETP (38). These findings suggest that adipose tissue contributes to 369 
plasma levels of this lipid transfer protein. In our study, we detected no correlation between CETP 370 
activity and BMI. However, CETP activity correlated with subcutaneous fat iliaca measured by caliper 371 
as well as several adipose tissue markers linked to diabetes progression suggesting that regional fat 372 
distribution could influence CETP activity. Indeed, CETP is predominantly expressed in subcutaneous 373 
adipose tissue compared to visceral adipose tissue (39). Furthermore, these associations were only 374 
present during pregnancy and not at follow-up suggesting an association between adipose tissue 375 
accumulation and CETP activity.  376 
Our study has several limitations. It is an observational study, and thus, we cannot explain the 377 
mechanisms underlying the findings. The low number of prediabetes at 5 years follow-up is the main 378 
weakness. However, our cohort is population based and we have not identified selection bias. In 379 
addition, the women in the study were young and early development of diabetes is important to 380 
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investigate on the way to discover alternative actions to delay the disease to further progress. The lack 381 
of associations at follow-up might thus be because the women are young and the metabolic 382 
complications have not been manifested yet. We could speculate that a longer follow-up might reveal 383 
increased levels of CETP in both the prediabetes group and in the women in the GDM group who are 384 
prone to develop type 2 diabetes. Further, more mechanistic and larger studies should replicate these 385 
findings.   386 
In conclusion, CETP activity was only modestly associated with HDL metabolism during 387 
pregnancy, but was more closely associated with sCD14 reflecting monocyte/macrophage activation. 388 
CETP activity during pregnancy identified women at risk for later diabetes development. Clearly, 389 
further investigations into the link between CETP activity, monocyte/macrophage activation and 390 
diabetes are warranted including experimental studies evaluating how these interactions are modified 391 
by CETP inhibition. If successful, such studies reveal novel treatment strategies to prevent 392 
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Table 1. Characteristics of prediabetes (n=20) vs. non-diabetes (n=270) diagnosed at follow-up 5 years after the index pregnancy  528 
Weeks of 
pregnancy 
14-16 22-24 30-32 36-38 FU 
Non-diabetes Prediabetes Non-diabetes Prediabetes Non-diabetes Prediabetes Non-diabetes Prediabetes Non-diabetes Prediabetes 
n 270 20 270 20 270 20 270 20 270 20 
Age, year 32.4 (3.8) 31.2 (4.7)       37.7 (3.8) 36.7 (4.8) 
Height, cm 169 (6) 170 (6)         
BMI, kg/m2 24 (22, 26) 25 (22, 28) 25 (23, 27) 26. (25, 29) 27 (24, 29) 27 (26, 30) 28 (25, 30 
) 
28 (26, 31) 23 (21, 25) 26 (24, 30)** 
Weight, kg 67 (61, 75) 72 (66, 82)* 71 (65, 78) 76 (69, 84)* 75 (69, 82) 79 (75, 89)* 78 (72, 85) 82 (76, 92) 65 (59, 72) 74 (70, 84)*** 
†Fat triceps 19 (15, 24) 21 (15, 27) 20 (15, 25) 21 (17, 27) 20 (15, 25) 20 (19, 29) 19 (15, 24) 19 (17, 26)   
†Fat subscapular 16 (13, 22) 22 (14, 30)* 18 (13, 25) 22 (17, 37)* 19 (14, 26) 22 (18, 39)* 19 (15, 28) 25 (14, 38)   
†Fat iliaca 23 (16, 32) 31 (22, 35)* 27 (21, 34) 31 (24, 39) 28 (22, 35) 35 (24, 40) 28 (22, 35) 33 (25, 37)   
SBP, mmHg 110 (100, 120) 110 (110, 120) 110 (100, 115) 113 (100, 120) 110 (105, 120) 110 (110, 130) 110 (105, 120) 110 (110, 130) 110 (100, 120) 120 (106, 130) 
DBP, mmHg 70 (60, 70) 70 (66, 74)* 65 (60, 70) 70 (65, 79)* 70 (60, 70) 70 (66, 79)* 70 (65, 80) 70 (70, 75) 70 (60, 75) 70 (69, 75) 
Insulin, pmol/L 26 (18, 37) 37 (30, 57)** 31 (20, 44) 46 (26, 69)* 39 (26, 61) 52 (33, 82)* 39 (26, 62) 48 (35, 132)* 22 (15, 32) 29 (26, 51)** 
Glucose, mmol/L 4.6 (4.3, 4.8) 4.9 (4.7, 5.2)***   4.5 (4.2, 4.7) 4.9 (4.6, 5.5)*** 4.4 (4.2, 4.7) 4.9 (4.3, 5.2)** 4.7 (4.4, 5.0) 5.6 (5.6, 5.9)*** 
Insulin sensitivity 210 (149, 296) 140 (87, 223)**   116 (77, 177) 70 (47, 127)**   250 (178, 339) 145 (70, 195)*** 
Insulin resistance 0.8 (0.5, 1.1) 1.2 (0.8,1.7)**   1.1 (0.7, 1.8) 1.5 (1.0, 3.0)** 1.12 (0.74, 1.80) 1.4(1.0,3.4)** 0.7 (0.4, 1.0) 1.1 (0.9,1.7)*** 
β-cell function 1.2 (0.9, 1.5) 0.8 (0.7, 0.8)***   0.9 (0.7, 1.2) 6.2 (0.4, 0.9)***   1.1 (0.8,1.4) 0.6 (0.5, 0.8)*** 
Data are given as mean±SD when normal distributed and median (25th, 75th) when skewed distributed ***p<0.001, **p<0.01, *p<0.05 vs. non-diabetes at 5 years follow-up, † Subcutaneous fat 529 











Table 2. Characteristics of GDM (n=70) diagnosed with WHO 2013 criteria vs. non-GDM (n=215).  539 
 14-16 22-24 30-32 36-38 FU 
 Non-GDM GDM Non-GDM GDM Non-GDM GDM Non-GDM GDM Non-GDM GDM 
n 215 70 215 70 215 70 215 70 215 70 
Age, year 32.0 (3.7) 33.0 (4.1)*       37.4 (3.7) 38.4 (4.2)* 
Height, cm 169 (6) 169 (6)         
BMI, kg/m2 24 (21, 25) 25 (23, 27)*** 25 (23, 27) 27 (24, 28)*** 26 (24, 28) 28 (26, 30)*** 27 (25, 30) 29 (26, 31)** 23 (21, 25) 25 (22, 27)*** 
Weight, kg 66 (61, 73) 72 (66, 78)*** 70 (64, 76) 76 (70, 83)*** 74 (68, 81) 80 (73, 87)*** 77 (71, 84) 82 (77, 89)*** 64 (59, 71) 70 (65, 78)*** 
†Fat triceps 19 (15, 23) 21 (16, 26)* 19 (15, 24) 21 (18, 26)** 19 (15, 25) 22 (17, 29)** 19 (14, 23) 20 (17, 29)**   
†Fat subscapular 16 (12, 21) 19 (14, 30)** 18 (13, 24) 22 (16, 34)*** 18 (14, 25) 21 (17, 33)** 19 (15, 27) 23 (17, 34)**   
†Fat iliaca 23 (16, 32) 28 (19, 36)* 26 (21, 33) 31 (23, 38)* 27 (22, 35) 31 (23, 37) 28 (22, 35) 30 (20, 35)   
SBP, mmHg 110 (100, 119) 110 (110, 120)** 110 (100, 115) 110 (104, 120) 112 (105, 120) 110 (110, 120) 110 (105, 120) 110 (110, 130)* 110 (100, 120) 110 (100, 120) 
DBP, mmHg 70 (60, 70) 70(60, 70) 65 (60, 70) 65 (60, 70) 70 (60, 70) 70 (60, 70) 70 (69, 80) 70 (65, 80) 70 (60, 75) 70 (64, 75) 
Insulin, pmol/L 25 (16, 36) 33 (26, 50)*** 28 (19, 41) 37 (26, 58)*** 35 (24, 53) 53 (39, 76)*** 36 (25, 61) 45 (34, 76)** 21 (15, 31) 29 (20, 40)*** 
Glucose, mmol/L 4.5 (4.3, 4.7) 5.0 (4.6, 5.2)***   4.4 (4.2, 4.6) 5.0 (4.6, 5.3)*** 4.4 (4.2, 4.6) 4.9(4.6, 5.2)*** 4.7 (4.4, 5.0) 5.0 (4.7, 5.3)*** 
Insulin sensitivity 223 (159, 314) 152 (104, 200)***   123 (86, 182) 76 (51, 121)***   256 (191, 349) 181(124, 270)*** 
Insulin resistance 0.70 (0.46, 1.04) 0.99(0.81, 1.61)***   1.0 (0.7, 4.5) 1.7 (1.1, 2.6)*** 1.0 (0.7, 1.7) 1.4 (1.0, 2.4)*** 0.6 (0.4, 0.9) 0.9 (0.6, 1.3)*** 
β-cell function 1.2 (1.0, 1.6) 0.8 (0.6, 1.1)***   1.0 (0.8, 1.3) 0.6 (0.4, 0.7)***   1.1 (0.9, 1.4) 0.8 (0.6, 1.2)*** 





Table 3. Plasma levels of adipokines, monocyte/macrophage and inflammation markers in non-diabetes vs. prediabetes 543 

















 14-16 22-24 30-32 36-38 FU 
 Non-diabetes Prediabetes Non-diabetes Prediabetes Non-diabetes Prediabetes Non-diabetes Prediabetes Non-diabetes Prediabetes 
Adipokines 
Adiponectin 8.5 (8.1-8.9) 7.5 (6.3-8.9) 7.8 (7.4-8.2) 6.3 (5.2-7.7) 7.0 (6.6-7.3) 7.2 (5.9-8.8) 7.1 (6.8-7.5) 6.9 (5.8-8.2) 7.8 (7.4-8.2) 6.3 (5.2-7.6) 
Leptin 43 (41-45) 44 (37-53) 47 (45-49) 46 (39-56) 52 (49-55) 54 (44-67) 50 (47-53) 52 (41-65) 27 (25-28) 32 (25-40) 
Resistin 35 (33-36) 40 (34-47) 37 (36-39) 42 (35-49) 38 (36-40) 34 (28-42) 42 (40-44) 43 (36-51) 27 (26-29) 32 (27-38) 
Chemerin 198 (192-204) 206 (184-231) 212 (206-219) 202 (179-227) 220 (213-228) 234 (206-267) 239 (231-247) 230 (202-260) 175 (170-181) 200 (177-226) 
Monocyte/macrophage markers 
sCD163 533 (508-558) 545 (457-651) 681 (648-717) 624 (517-754) 734 (696-775) 718 (586-878) 792 (754-831) 742 (619-890) 503 (479-528) 515 (430-618) 
sCD14 2.7 (2.6-2.8) 3.1 (2.6-3.6) 2.8 (2.7-2.9) 2.8 (2.4-3.2) 3.1 (2.9-3.2) 3.5 (3.0-4.1) 3.2 (3.1-3.3) 3.4 (3.0-3.9) 3.2 (3.1-3.3) 3.5 (3.1-4.0) 
Inflammatory markers 
CRP 1.5 (1.4-1.6) 1.9 (1.4-2.7) 1.5 (1.4-1.7) 2.2 (1.6-3.0) 1.3 (1.2-1.4) 1.7 (1.2-2.4) 1.3 (1.2-1.4) 1.5 (1.0-2.1) 0.4 (0.3-0.4) 0.6 (0.4-1.0) 
22 
 
Table 4. CETP activity associated with clinical variables, lipoproteins, adipokines, monocyte/macrophage and inflammatory markers during pregnancy and follow-up (n=290) 561 






5 year follow-up 
14-16 
  UNI  UNI  UNI  UNI  UNI  UNI 
 B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value 
Age 0.01 (-0.01-0.01) 0.367   0.01 (-0.01-0.01) 0.534   -0.01 (-0.01-0.01) 0.443   
Systolic BP     0.01 (-0.35-0.36) 0.983   -0.58 (-1.46-0.30) 0.193   
Diastolic BP -0.07 (-0.38-0.24) 0.663   0.04 (-0.25-0.32) 0.805   -0.39 (-1.10-0.32) 0.279   
Body composition             
BMI 0.16 (-0.10-0.42) 0.227   0.25 (-0.01-0.51) 0.060   -0.47 (-1.04-0.10) 0.107   
Weight 0.25 (0.01-0.49) 0.043   0.28 (0.03-0.52)  0.028   -0.25 (-0.80-0.30) 0.374   
Sub. fat triceps 0.09 (-0.17-0.34) 0.504   0.18 (-0.05-0.41) 0.119       
Sub. fat iliaca 0.34 (0.15-0.53) 0.001 0.28 (0.08-0.47) 0.005 0.30 (0.09-0.52) 0.006       
Glucose metabolism             
Insulin 0.06 (-0.01-0.12) 0.062   0.09 (0.03-0.15) 0.003   -0.11 (-0.25-0.03) 0.133   
Glucose 0.49 (0.04-0.95) 0.032   0.08 (-0.31-0.46) 0.703   0.01 (-0.85-0.85) 0.993   
Insulin sensitivity -0.07 (-0.14- -0.01) 0.036   -0.10 (-0.16- -0.03) 0.003   0.03 (-0.13-0.19) 0.689   
Insulin resistance 0.06 (0.01-0.13) 0.038   0.08 (0.03-0.14) 0.004   -0.10 (-0.23-0.04) 0.159   
β-cell function -0.11 (-0.20--0.01) 0.027   -0.05 (-0.13-0.04) 0.258   0.07 (-0.03-0.16) 0.149   
Lipoproteins              
LDL-C 0.16 (0.04-0.29) 0.013   0.11 (-0.01-0.22) 0.063   0.14 (-0.01-0.29) 0.056 0.14 (0.00-0.29) 0.050 
HDL-C -0.26 (-0.43- -0.10) 0.001 -0.19 (-0.35- -0.03) 0.021 -0.09 (-0.23-0.04) 0.169   -0.04 (-0.20, 0.13) 0.679   
TG 
 
0.10 (-0.01-0.21) 0.061   -0.03 (-0.14-0.09) 0.638   -0.05 (-0.17-0.06) 0.335   
Adipokines             
Adiponectin 0.04 (-0.06-0.13) 0.469   0.01 (-0.08-0.08) 0.994   0.05 (-0.04-0.14) 0.300   
Leptin 0.07 (-0.01-0.13) 0.054   0.11 (0.05-0.17) 0.001 0.10 (0.04-0.17) 0.002 0.02 (-0.04-0.08) 0.585   
Resistin 0.16 (0.05-0.26) 0.003 0.12 (0.01-0.22) 0.032 -0.01 (-0.09-0.08) 0.846   0.05 (-0.06-0.163) 0.337   
Chemerin 0.29 (0.16-0.43) <0.001   0.12 (-0.01-0.24) 0.064   0.09 (-0.05-0.23) 0.204   
Monocyte/macrophage markers            
CD163 0.15 (0.06-0.24) 0.001   0.09 (0.01-0.17) 0.021   0.09 (-0.01-0.19) 0.080   
CD14 0.22 (0.11-0.33) <0.001 0.17 (0.06-0.28) 0.004 0.19 (0.07-0.30) 0.001 0.16 (0.05-0.28) 0.007 0.24 (0.10-0.38) 0.001 0.24 (0.11-0.38) <0.001 
Inflammatory markers             
23 
 
CRP 0.07 (0.02-0.12) 0.007   0.04 (-0.01-0.09) 0.079   0.02 (-0.02-0.06) 0.239   
#The association of the lipoprotein data and CETP activity is from week 36-38 instead of 30-32 week. Numbers are correlation coefficient, slope (beta) and p-values. 562 
24 
 
Table 5. Uni and multivariable logistic and linear regression identifying the strongest predictors of prediabetes and 2h glucose during OGTT after 5 years follow-up 563 
 Prediabetes at 5 years follow-up 2h glucose 5 years after pregnancy 
 Univariate Multivariable Univariate Multivariable 
 Slope RR (95% CI) P Slope RR (95% CI) P Slope (95% CI) P Slope (95% CI) P 
Age -0.08 0.92 (0.82-1.04) 0.177 -0.11 0.90 (0.78-1.03) 0.129 0.00 (-0.04-0.03) 0.77   
BMI 0.39 1.48 (0.97-2.27) 0.070 -0.05 0.95 (0.52-1.74) 0.901 0.31 (0.20-0.42) <0.001 0.10 (-0.08-0.27) 0.27 
Diabetes in family 0.53 1.69 (0.71-4.05) 0.24    0.16 (-0.08-0.40) 0.20 0.08 (-0.15-0.32) 0.48 
Parity 0.56 1.75 (0.67-4.59) 0.25    0.12 (-0.12-0.36) 0.32   
LDL-C 0.11 1.11 (0.70-1.76) 0.65    0.09 (-0.02-0.21) 0.117 0.02 (-0.09-0.13) 0.73 
HDL-C -0.55 0.58 (0.26-0.92) 0.021 -0.05 0.95 (0.52-1.74) 0.87 -0.26 (-0.37- -0.15) <0.001 -0.09 (-0.21-0.03) 0.157 
β-cell function -1.10 0.33 (0.20-0.57) <0.001 -1.05 0.35 (0.19-0.66) 0.001 -0.34 (-0.45- -0.22) <0.001 -0.22 (-0.34- -0.10) <0.001 
CETP 0.68 1.97 (1.20-3.24) <0.001 0.75 2.13 (1.18-3.81) 0.012 0.22 (0.11-0.34) <0.001 0.15 (0.03-0.27) 0.012 
Resistin 0.33 1.40 (0.89-2.20) 0.149 0.30 1.35 (0.76-2.39) 0.30 0.12 (0.00-0.24) 0.045 0.10 (-0.02-0.21) 0.099 
Chemerin 0.23 1.26 (0.80-1.98) 0.33    0.19 (0.07-0.30) 0.002 -0.08 (-0.22-0.06) 0.28 
Leptin 0.40 1.49 (0.92-2.42) 0.106 0.15 1.16 (0.52-2.58) 0.72 0.31 (0.19-0.42) <0.001 0.16 (-0.01-0.21) 0.064 
sCD163 0.13 1.14 (0.72-1.80) 0.59    0.21 (0.09-0.32) 0.001 0.07 (-0.06-0.20) 0.30 
sCD14 0.27 1.31 (0.81-2.11) 0.27    0.11 (0.00-0.23) 0.062 0.06 (-0.08-0.19) 0.41 




















Table 6. Influence of covariates on the association between CETP at 14-16 weeks and  582 
prediabetes and 2h glucose 5 years after pregnancy. 583 
 Prediabetes at 5 years follow-up 2h glucose 5 years after pregnancy 
 Slope RR (95% CI) P   
CETP Unadjusted 0.68 1.97 (1.20-3.24) 0.007 0.23 (0.11-0.34) <0.001 
Adjusted by:      
Age 0.70 2.01 (1.22-3.31) 0.006 0.23 (0.11-0.35) <0.001 
BMI 0.79 2.19 (1.29-3.73) 0.004 0.22 (0.11-0.33) <0.001 
Diabetes in family 0.70 2.00 (1.22-3.30) 0.006 0.23 (0.11-0.35) <0.001 
Parity 0.72 2.06 (1.23-3.45) 0.006 0.23 (0.11-0.35) <0.001 
LDL-C 0.68 1.97 (1.19-3.24) 0.008 0.22 (0.10-0.34) <0.001 
HDL-C 0.63 1.87 (1.13-3.10) 0.015 0.19 (0.07-0.30) 0.001 
β-cell function 0.62 1.85 (1.10-3.12) 0.021 0.19 (0.07-0.31) 0.002 
Resistin 0.67 1.95 (1.17-3.24) 0.010 0.21 (0.10-0.33) <0.001 
Chemerin 0.66 1.94 (1.16-3.23) 0.011 0.19 (0.07-0.31) 0.002 
Leptin 0.67 1.96 (1.18-3.26) 0.010 0.20 (0.08-0.31) 0.001 
sCD163 0.68 1.97 (1.19-3.24) 0.008 0.20 (0.08-0.31) 0.001 
sCD14 0.65 1.92 (1.16-3.18) 0.012 0.21 (0.09-0.33) <0.001 
 584 
BMI, body mass index; CETP, cholesteryl ester transfer protein; LDL-C, low-density lipoprotein cholesterol;  585 












Figure 1. Lipoproteins and lipids during pregnancy and 5 years follow-up in prediabetes, GDM and 596 
control women. In the figure GDM is present both in the GDM group and in the control group. 597 
Statistics is performed comparing prediabetes vs. non-diabetes (*) and GDM vs. non-GDM (†) at each 598 




















Figure 2. CETP activity during pregnancy and 5 years follow-up in GDM, prediabetes and control 617 
women. * p<0.05 ** p<0.01 between non-diabetes vs. pre-diabetes. P-values denote group effect from 618 


















Figure 3. Association between CETP and sCD14 during pregnancy. Circulating CETP activity and 635 
sCD14 levels at A. week 14-16 and B. expressed as area under the curve (AUC) for both markers 636 
during normal pregnancy, in GDM and in women with prediabetes at 5 years follow-up. **p<0.01 vs. 637 
Normal pregnancy in A/B. C. correlation between AUC’s for sCD14 and CETP. Correlation 638 
coefficients and p-values are from Spearman correlation. D. Associations (Spearman) between CETP 639 
and sCD14 at different time-points during pregnancy in normal pregnancy, prediabetes and GDM. E. 640 
Interaction analysis of 2-hour glucose levels at 5-year follow-up. F. product of CETP and sCD14 641 
tertiles (i.e. CETP tertile*sCD14 tertile) which gives 6 groups: group 1: Tertile 1 (T1) of both CETP 642 
and sCD14; group 2: combinations of T1 and T2 of CETP and sCD14; group 3: combinations of T1 643 
and T3 of CETP and sCD14; group 4: T2 of both; group 5: combinations of T2 and T3 of CETP and 644 
sCD14; group 6: T3 of both. **p<0.01 vs. group 1-3. 645 
646 
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